GPCR Structure Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—
Leverage & solvency
Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $225.25M | $108.81M | $70.10M | $36.19M |
| SG&A expense | $61.55M | $49.41M | $32.67M | $16.37M |
| Operating income | -$176.56M | -$158.23M | -$102.78M | -$52.56M |
| Pretax income | -$140.69M | -$122.22M | -$89.38M | -$51.30M |
| Income tax | $515,000 | $310,000 | $236,000 | $17,000 |
| Net income | -$141.20M | -$122.53M | -$89.62M | -$51.32M |
| EBITDA | -$175.23M | -$157.24M | -$102.48M | -$52.28M |
| EPS (basic) | -0.80 | -0.78 | -0.81 | -5.51 |
| EPS (diluted) | -0.80 | -0.78 | -0.81 | -5.51 |
| Weighted avg. shares (diluted) | 177.60M | 157.92M | 110.20M | 9.58M |
| Balance sheet | ||||
| Cash & equivalents | $799.62M | $169.51M | $129.79M | $26.09M |
| Short-term investments | $646.57M | $714.01M | $337.53M | $64.75M |
| Current assets | $1.57B | $891.21M | $473.61M | $93.09M |
| PP&E, net | $6.65M | $3.48M | $3.23M | $1.03M |
| Total assets | $1.58B | $903.33M | $482.02M | $97.84M |
| Current liabilities | $63.28M | $36.02M | $24.74M | $13.01M |
| Total liabilities | $67.54M | $38.49M | $29.05M | $13.01M |
| Shareholders' equity | $1.52B | $864.84M | $452.97M | -$115.14M |
| Shares outstanding | 212.51M | 171.86M | 139.22M | 10.53M |
| Cash flow statement | ||||
| Operating cash flow | -$222.20M | -$116.64M | -$79.49M | -$46.12M |
| Capital expenditure | $3.61M | $1.29M | $2.17M | $155,000 |
| Free cash flow | -$225.81M | -$117.93M | -$81.66M | -$46.27M |
| Investing cash flow | $89.80M | -$358.91M | -$268.34M | -$62.11M |
| Financing cash flow | $762.52M | $515.26M | $451.53M | $29.01M |
| Depreciation & amortization | $1.33M | $992,000 | $295,000 | $277,000 |
| Stock-based compensation | $28.99M | $18.79M | $8.19M | $2.51M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.